#Japan #Tokyo #NEXTBIOMEDICAL #Nexsphere-F #ASAHI INTECC

NEXTBIOMEDICAL's Landmark Agreement in Japan

In an exciting development for the medical device landscape, NEXTBIOMEDICAL CO., LTD., a South Korean innovator in the field, has secured an exclusive distribution agreement with Asahi Intecc Co., Ltd., a recognized global player in medical devices. This agreement, set to enhance the company's reach, focuses on Nexsphere-F™, NEXTBIOMEDICAL’s innovative fast-resorbable microsphere designed for embolization.

The partnership is groundbreaking not only for its potential impact on patient care in Japan but also for how NEXTBIOMEDICAL conducts its operations. Unlike many biotech firms that rely on technology transfers and royalties for revenue, NEXTBIOMEDICAL's model emphasizes direct exports of finished medical devices. The company aims to leverage Asahi Intecc's strong market presence to drive Nexsphere-F™’s entry into Japan effectively.

Asahi Intecc: A Respected Partner

Asahi Intecc is renowned for its specialization in medical microcatheters and guidewires. The firm’s extensive global footprint includes operations across Japan, the United States, Europe, China, and India. Their products are critical to various vascular interventional procedures, making them an ideal partner for NEXTBIOMEDICAL.

Their vast distribution network spans approximately 120 countries, positioning them as a formidable force in the medical device market. Notably, Asahi Intecc has a significant footprint in the vascular intervention sector, where they continue to expand their offerings to meet the rising demand for minimally invasive treatments. A prime example of their influence is their collaboration with leading medical practitioners, such as Dr. Yuji Okuno, who is recognized for his contributions to musculoskeletal embolization techniques.

Reportedly, Asahi Intecc reached an impressive revenue of JPY 120 billion at the conclusion of fiscal year 2025—a 12% increase from the previous year—with an operating profit margin of 25.1%. With around 90% of revenue stemming from their medical device segment, they are positioned to continue their expansion into various international markets.

NEXTBIOMEDICAL anticipates that Asahi Intecc’s robust network will significantly streamline the process for introducing Nexsphere-F™ into the Japanese market.

The Nexsphere-F™ Advantage

Nexsphere-F™, NEXTBIOMEDICAL's flagship solution, is designed specifically for embolization targeting musculoskeletal pain, setting a new standard in treatment options. The microsphere has already received regulatory nods from the Ministry of Food and Drug Safety (MFDS) in Korea as well as CE-MDD certification in Europe. Furthermore, it has gained approval from Health Canada, demonstrating its acceptance on a global scale. Currently, post-market clinical studies are well underway, and NEXTBIOMEDICAL is actively pursuing U.S. FDA approval, aimed for completion between 2027 and 2028.

Through this exclusive agreement, NEXTBIOMEDICAL seeks to fast-track its ventures in the Japanese medical market. Collaboration on obtaining approvals and reimbursement processes with Asahi Intecc is expected to significantly aid this initiative.

A spokesperson from NEXTBIOMEDICAL remarked, "This agreement underscores the strong recognition of our product’s competitiveness and global market potential. We are committed to accelerating our market presence in Japan by leveraging Asahi Intecc's established sales network."

Additionally, the expert noted, "This exclusive arrangement serves as a pivotal moment for Nexsphere-F™’s global expansion strategy. Our aim is to foster impactful results in Japan through effective collaboration with local medical professionals and partners.”

With this strategic partnership, NEXTBIOMEDICAL not only enhances its own market position but also contributes significantly to improving treatment options available for conditions like osteoarthritis in Japan. The potential benefits for patients and physicians alike are immense, marking a new chapter in the collaboration between innovative medical technologies and healthcare solutions in Asia’s robust markets.